跳至主要内容
临床试验/NCT01236014
NCT01236014已完成不适用

Indirect Comparison of Efficacy of Treatments for Idiopathic Immune Thrombocytopenic Purpura - Review of Platelet Responses and Bleeding Events

GlaxoSmithKline0 个研究点目标入组 1 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1
主要终点
Durable response: platelet count of >=50 and <400 Gi/L

研究概览

简要总结

An indirect comparison to compare the efficacy of eltrombopag versus romiplostim

详细描述

An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator

研究设计

研究类型
Observational
观察模型
Other
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults with ITP
  • Pre-specified treatment
  • Prospective clinical studies with at least 10 patients

排除标准

  • Adults with ITP for other reasons

研究组 & 干预措施

Eltrombopag & standard of care

干预措施: Eltrombopag (Drug)

Romiplostim & standard of care

干预措施: Romiplostim (Drug)

Standard of care

干预措施: Placebo (Drug)

结局指标

主要结局

Durable response: platelet count of >=50 and <400 Gi/L

时间窗: 6 months

Overall response: either a durable response or a transient platelet response

时间窗: 6 months

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验